As part of the CURE® Educated Patient® Gynecologic Cancers Summit, an expert explained the basics of biomarkers and the ...

The global cancer biomarkers market size is anticipated to grow from USD 24.08 billion to USD 78.20 billion in 10 years. The market will experience rapid growth due to the rising demand for ...

Lunit’s AI-powered biomarker, Lunit SCOPE PD-L1 TPS, integrates into Roche’s navify® Digital Pathology platform to enhance ...

Researchers have identified five independent factors that predict cancer patients' response to checkpoint inhibitors (CPIs). The study validates these factors in more than 1,400 patients and diverse ...

Sunil Verma, MD, of AstraZeneca envisions the future of cancer care, including the role of AI and streamlining screening ...

This report is a review of recent and emerging trends that promise to make radiation oncology for prostate cancer more ...

Through communication and education, patients with metastatic breast cancer may be able to balance treatment with quality of ...

Researchers have discovered new insights into tumor-induced B cell changes in blood and bone marrow of triple negative breast cancer patients. The findings show two distinct patterns of B cell ...

Moffitt will assess Cizzle’s biomarker assay for early lung cancer detection with the aim to reduce false positives caused by ...

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute ...

The antibody-drug conjugate (ADC) is currently under review by the FDA as a treatment for advanced or metastatic non-squamous ...

Biomarker testing is critical for determining optimal therapy early in the non–small lung cancer (NSCLC) treatment process, ...